Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuya Yoshida

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
Nature Communications|May 14, 2021
Alteration of circadian machinery in monocytes underlies chronic kidney disease-associated cardiac inflammation and fibrosisYuya Yoshida, Naoya Matsunaga, Takaharu Nakao, et al.
Biochemical and Biophysical Research Communications|February 15, 2025
Dopamine receptor D3 affects the expression of Period1 in mouse cells via DRD3-ERK-CREB signalingMasaki Matsuda, Takumi Nishi, Yuya Yoshida, et al.
Scientific Reports|November 15, 2024
Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumabYuki Kasahara, Ken Saijo, Reio Ueta, et al.
European Journal of Cancer (Oxford, England : 1990)|May 26, 2026
Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapyShiori Ishikawa, Kota Ouchi, Shonosuke Wakayama, et al.
Anticancer Research|November 29, 2023
FOLFIRI Chemotherapy for Patients With Metastatic Urachal CarcinomaSakura Hiraide Taniguchi, Keigo Komine, Noriko Takenaga, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 29, 2026
A transient, B cell-targeted tolerance switch using nanoparticles loaded with metabolizable AhR agonists for antigen-specific immune regulationTakanatsu Hosokawa, Takuro Yamada, Gyeongwoo Lee, et al.
Discover Oncology|April 7, 2025
A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phaseKen Saijo, Hiroo Imai, Yuki Kasahara, et al.
Inorganic Chemistry|July 21, 2022
Topochemical Synthesis of LiCoF<sub>3</sub> with a High-Temperature LiNbO<sub>3</sub>-Type StructureYumi Matsuo, Yuko Matsukawa, Masahiro Kitakado, et al.
International Journal of Clinical Oncology|February 28, 2025
Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test databaseSakura Hiraide Taniguchi, Masanobu Takahashi, Shih-Wei Chiu, et al.
Oncology|September 14, 2023
Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell CarcinomaReio Ueta, Hiroo Imai, Ken Saijo, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
Nature Communications|May 14, 2021
Alteration of circadian machinery in monocytes underlies chronic kidney disease-associated cardiac inflammation and fibrosisYuya Yoshida, Naoya Matsunaga, Takaharu Nakao, et al.
Biochemical and Biophysical Research Communications|February 15, 2025
Dopamine receptor D3 affects the expression of Period1 in mouse cells via DRD3-ERK-CREB signalingMasaki Matsuda, Takumi Nishi, Yuya Yoshida, et al.
Scientific Reports|November 15, 2024
Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumabYuki Kasahara, Ken Saijo, Reio Ueta, et al.
European Journal of Cancer (Oxford, England : 1990)|May 26, 2026
Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapyShiori Ishikawa, Kota Ouchi, Shonosuke Wakayama, et al.
Anticancer Research|November 29, 2023
FOLFIRI Chemotherapy for Patients With Metastatic Urachal CarcinomaSakura Hiraide Taniguchi, Keigo Komine, Noriko Takenaga, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 29, 2026
A transient, B cell-targeted tolerance switch using nanoparticles loaded with metabolizable AhR agonists for antigen-specific immune regulationTakanatsu Hosokawa, Takuro Yamada, Gyeongwoo Lee, et al.
Discover Oncology|April 7, 2025
A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phaseKen Saijo, Hiroo Imai, Yuki Kasahara, et al.
Inorganic Chemistry|July 21, 2022
Topochemical Synthesis of LiCoF<sub>3</sub> with a High-Temperature LiNbO<sub>3</sub>-Type StructureYumi Matsuo, Yuko Matsukawa, Masahiro Kitakado, et al.
International Journal of Clinical Oncology|February 28, 2025
Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test databaseSakura Hiraide Taniguchi, Masanobu Takahashi, Shih-Wei Chiu, et al.
Oncology|September 14, 2023
Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell CarcinomaReio Ueta, Hiroo Imai, Ken Saijo, et al.
Pageof 12